GC CELL CORPORATION
KKRX:14451013,280.00
KRW
-180.00
(-1.34%)
ISIN
KR7144510005
Return %
Stock
S&P 500
1Y
-36.91
14.39
3Y
-54.75
81.42
5Y
-86.75
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jae-Wang Kim
- Full Time Employees
- 806
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 107, Ihyeon-ro Yongin-si GY South Korea 16924
- IPO Date
- Jun 23, 2016
- Website
- gclabcell.com
- Similar Companies
- Business
- GC Cell Corporation is a South Korea-based biotechnology company specializing in the development, manufacturing, and commercialization of cell and gene therapy products. Its core offerings include autologous and allogeneic immune cell therapies with platforms such as CAR-NK, CAR-T, and CIK cells; key products include Immuncell-LC, an adjuvant therapy for liver cancer post-tumor resection. The company also provides comprehensive cell therapy contract development and manufacturing services (CDMO), including cell banking, cold-chain logistics, sample inspection, clinical trial material supply, GMP-level quality analysis, and bio-logistics solutions. GC Cell operates globally with its headquarters in Yongin, South Korea, and is a subsidiary of the Korean pharmaceutical group Green Cross Corporation. Founded in 2015, GC Cell is active in advancing cell therapy innovation from research to commercialization, serving cancer patients worldwide with flexible supply chain services. In recent developments, GC Cell has expanded its global footprint through strategic partnerships and business agreements. In 2024, it entered into a strategic cooperation agreement with Lukas Biomedical to jointly develop cell therapies targeting Korean and Taiwanese markets. In 2025, GC Cell began dosing patients in a Phase 1 clinical trial for GCC2005, a CAR-NK therapy for T-cell lymphoma, and signed a key partnership with PT Bifarma Adiluhung for technology transfer of Immuncell-LC in Indonesia. In October 2025, GC Cell formed a partnership with IASO Bio to commercialize CAR-T therapy for multiple myeloma in Korea, marking a major step in its global strategy for cell therapy commercialization. It also completed a process transfer agreement with US-based BioCentriq to bring Immuncell-LC to the U.S. market, enhancing its international presence. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. These strategic moves reinforce GC Cell's position as a global leader in advanced cell and gene therapy and its commitment to expanding innovative treatment options worldwide.